Source：The Insides Company Limited
On：30th June 2025
Organisation：The Insides Company Limited, Medella S.A.
The Insides Company, a medical technology company focused on the development and commercialisation of novel chyme reinfusion therapy (CRT) devices for the treatment of intestinal failure today announced Medella S.A. based in Gerakas, Athens as the exclusive partner for Greece following the signing of the distribution agreement.
Garth Sutherland, CEO of The Insides Company, commented：
“We are thrilled to launch our life-saving technology in Greece through a new partnership with Medella. Their strong portfolio and proven expertise in clinical nutrition make them an ideal distribution partner as we introduce the clinical benefits of chyme reinfusion therapy in Greece—widely regarded as the birthplace of modern medicine.“
Michalis Drakatos – Managing Director Medella S.A.
"With this agreement now signed, we are excited to introduce this innovative technology to Greece. Our company remains committed to offering healthcare products and services that significantly improve quality of life. Our team, experts in clinical nutritional care for almost 20 years, are really looking forward to partnering with The Insides® Company to embrace the adoption of this solution, support nutritional status, enhance gut function and improve the quality of life and outcomes of patients across the country”
Type II (or sometimes called acute) intestinal failure is the inability of the gut to absorb enough water, nutrients, and electrolytes to sustain life without intravenous (parenteral nutrition) support. It can result from conditions like malabsorption, short bowel syndrome, fistulae, dysmotility, or obstruction. After colorectal surgery, patients often have an enterostomy to divert the nutritionally rich intestinal contents (chyme) during healing. This is typically left open for 6–12 months, during which the discarded chyme can lead to intestinal failure and complications.
The Insides System is an innovative medical device designed for chyme reinfusion therapy, a recommended technique for managing high-output enterocutaneous fistulas and enterostomies. This therapy helps return chyme to the patient's digestive tract, serving as a complementary nutritional support alongside other treatment methods.
About Medella S.A.
Founded in 2006, Medella has extensive experience of the Greek pharmaceutical and clinical nutrition market. Over the years, Medella has built a strong reputation as a trusted partner of major international companies, offering a wide range of clinical nutrition products and medical devices, such as wound management solutions, medical solutions for prevention and treatment of catheter infections, supporting patients in Greece. This is resulting in improvements to the quality of their life. More recently Medella has also commenced in the domestic production of clinical nutrition and nutritional supplements.
About The Insides Company
The Insides Company is a pioneering health-tech company focused on revolutionizing the field of intestinal recovery. Through its innovative Chyme Reinfusion Therapy system, the company aims to enhance patient outcomes by improving digestion and nutrient absorption. The Insides® Company collaborates with leading medical professionals and institutions to bring cutting-edge solutions to patients worldwide, improving quality of life and supporting long-term health.
Contacts
Medella S.A.
Rea Salateli, Marketing Manager
Telephone： +30 21068 21 214
Email：rsalateli@medella.gr
The Insides Company Limited
Garth Sutherland, CEO
Phone：+64 9 887 9309
Email：sales@theinside.co
© 2025 The Insides Company. All copyright, design, patent and intellectual property rights existing in our designs and products and in the images, text and design of our website / marketing material are the property of The Insides Company.
.png){kind=small}
.png){kind=small}
